Frequent Questions
The following FAQs provide technical information about multi-panel urine drug test cups and related screening products. They cover commonly asked questions regarding testing methodology, cut-off levels, result interpretation, and general use considerations.
These products are designed for screening purposes only. Any presumptive positive result should be confirmed using appropriate laboratory-based confirmatory testing in accordance with applicable policies or requirements.
The information below is intended to support consistent and informed use of urine drug screening devices.
UA multi-panel cups use lateral flow immunoassay technology to screen urine for drug metabolites at established cut-off thresholds.
All cup and strip products provide qualitative screening results only. They do not report concentration values.
The cut-off level is the predefined concentration at which a result is reported as presumptive positive under immunoassay screening standards.
No. All positive results are presumptive and require confirmation by GC/MS or LC/MS for clinical, regulatory, or legal purposes.
CLIA-waived cups are intended for point-of-care clinical screening, while forensic-use-only cups are not intended for medical decision-making or diagnosis.
Yes. Lower cut-off configurations are designed to detect lower metabolite concentrations and may identify recent or low-level use.
Yes. Cross-reactivity with certain prescription or OTC medications may occur depending on the analyte and assay design.
Dilution can reduce analyte concentration and may impact screening outcomes. Specimen validity indicators should be reviewed when present.
Yes. Any visible test line, regardless of intensity, is interpreted as negative under immunoassay screening rules.
No. Urine screening detects drug metabolites, not impairment or current intoxication.
Typical panels include AMP, BAR, BUP, BZO, COC, MET, OPI, MTD, OXY, PCP, THC, MDMA, ETG, Fentanyl, and others depending on panel count.
Forensic-use-only cups may be used in monitored collections, but confirmatory testing protocols must be followed when required.